Neumora Therapeutics, Inc. Common Stock
NMRAHealthcare|Biotechnology|US
$0.50
+0.02 (+3.35%)
DCF Value
$1.10
Tangible Book / Share
$0.24
Cash / Share
$0.63
Analyst Consensus
Buy9 analysts
Strong Buy
0
Buy
6
Hold
1
Sell
2
Strong Sell
0
Consensus Target
$4.50
Implied Upside
+794.1%
Low Target
$4.00
High Target
$5.00
Price Target Trend
Last Month
—
0 targets
Last Quarter
—
0 targets
Last Year
$6.00
5 targets · +1092% vs price
All Time
$14.07
14 targets · +2696% vs price
Rating Trend
Dec 25
5 buy · 3 hold · 1 sell
Jan 26
6 buy · 2 hold · 1 sell
Feb 26
7 buy · 2 hold · 1 sell
Mar 26
7 buy · 1 hold · 1 sell
Apr 26
7 buy · 1 hold · 1 sell
May 26
7 buy · 1 hold · 1 sell
Jun 26
7 buy · 1 hold · 1 sell
Jul 26
7 buy · 1 hold · 1 sell
Aug 26
7 buy · 1 hold · 1 sell
Sep 26
7 buy · 1 hold · 1 sell
Oct 26
7 buy · 1 hold · 1 sell
Nov 26
7 buy · 1 hold · 1 sell
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 13, 2026 | RBC Capital | Brian Abrahams | $5.00(+213%) | $1.59 | TheFly |
| Jun 18, 2026 | Mizuho Securities | $4.00(+167%) | $1.50 | TheFly | |
| Jan 12, 2026 | Leerink Partners | Marc Goodman | $8.00(+252%) | $2.27 | TheFly |
| Jan 5, 2026 | Mizuho Securities | Graig Suvannavejh | $6.00(+249%) | $1.72 | StreetInsider |
| Dec 1, 2025 | RBC Capital | $7.00(+212%) | $2.24 | TheFly | |
| Oct 28, 2025 | Needham | $8.00(+208%) | $2.60 | TheFly | |
| Mar 7, 2025 | Stifel Nicolaus | $2.00(+34%) | $1.49 | TheFly | |
| Jan 2, 2025 | RBC Capital | Brian Abrahams | $4.00(+103%) | $1.97 | StreetInsider |
| Jul 22, 2024 | Needham | Ami Fadia | $23.00(+104%) | $11.28 | TheFly |
| Jul 8, 2024 | Mizuho Securities | Graig Suvannavejh | $20.00(+95%) | $10.25 | TheFly |
| Jun 17, 2024 | RBC Capital | Brian Abrahams | $29.00(+199%) | $9.71 | StreetInsider |
| Mar 13, 2024 | RBC Capital | Brian Abrahams | $31.00(+109%) | $14.81 | StreetInsider |
| Oct 10, 2023 | Stifel Nicolaus | Paul Matteis | $26.00(+138%) | $10.91 | Benzinga |
| Oct 10, 2023 | RBC Capital | Brian Abrahams | $24.00(+120%) | $10.91 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| RBC Capital | maintain | Outperform | Jul 13, 2026 |
| Mizuho | maintain | Outperform | Jun 18, 2026 |
| Needham | maintain | Buy | Jun 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 16, 2026 |
| Guggenheim | maintain | Buy | Mar 31, 2026 |
| Needham | maintain | Buy | Mar 31, 2026 |
| William Blair | upgrade | Market Perform →Outperform | Feb 17, 2026 |
| RBC Capital | upgrade | Sector Perform →Outperform | Dec 1, 2025 |
| Stifel | maintain | Hold | Nov 17, 2025 |
| Needham | maintain | Buy | Oct 28, 2025 |
| Guggenheim | upgrade | Neutral →Buy | Oct 27, 2025 |
| JP Morgan | downgrade | Neutral →Underweight | Sep 16, 2025 |
| Mizuho | maintain | Outperform | Jul 16, 2025 |
| Needham | maintain | Buy | May 13, 2025 |
| Needham | maintain | Buy | Apr 10, 2025 |
| B of A Securities | downgrade | Buy →Underperform | Apr 2, 2025 |
| Guggenheim | downgrade | Buy →Neutral | Mar 10, 2025 |
| Stifel | downgrade | Buy →Hold | Mar 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2025 |
| RBC Capital | maintain | Sector Perform | Mar 4, 2025 |
| Needham | maintain | Buy | Mar 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 14, 2025 |
| B of A Securities | maintain | Buy | Jan 6, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 3, 2025 |
Earnings History
Next report: Mar 10, 2027 · EPS est. $-0.17| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.23 | $-0.24 | — | — |
| May 7, 2026 | $-0.30 | $-0.32 | — | — |
| Mar 16, 2026 | $-0.35 | $-0.34 | — | — |
| Nov 6, 2025 | $-0.35 | $-0.34 | — | — |
| Aug 6, 2025 | $-0.33 | $-0.38 | — | — |
| May 12, 2025 | $-0.42 | $-0.40 | — | — |
| Mar 3, 2025 | $-0.37 | $-0.46 | — | — |
| Nov 12, 2024 | $-0.45 | $-0.38 | — | — |
News
Biotech Options Buzz: UTHR, NMRA, EWTX
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
Sep 18, 2026schaeffersresearch.com
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026
Aug 14, 2026globenewswire.com